Skip to main content

Table 2 Association of Baseline Blood Biomarkers and Outcomes

From: Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

 

Multivariate Model for PFS

 

Multivariate Model for OS

 

Biomarker

HR (95% CI)a, N = 157

P Valuea

HR (95% CI)a, N = 157

P Valuea

WBC

1.01 (0.97–1.05)

.68

1.04 (0.99–1.09)

.10

ANC

1.01 (0.97–1.06)

.55

1.04 (1.00–1.09)

.08

ANC ≥ 7.5

1.05 (0.68–1.63)

.81

1.86 (1.09–3.19)

.02

ALC

0.78 (0.56–1.10)

.15

0.86 (0.56–1.31)

.48

ANC/ALC

1.04 (1.02–1.06)

<.001

1.04 (1.02–1.06)

<.001

ANC/ALC ≥ 5.9

1.61 (1.14–2.28)

.008

1.87 (1.16–3.02)

.01

AMC ≥ 0.63

1.50 (1.06–2.12)

.02

1.59 (0.88–2.90)

.13

AEC

0.43 (0.15–1.29)

.13

1.71 (1.06–2.75)

<.03

Platelets (per 50 unit increase)

1.03 (0.95–1.11)

.48

0.29 (0.06–1.55)

.15

M:L

1.04 (1.02–1.06)

<.001

1.05 (0.95–1.15)

.34

M:L ≥ 11.3

1.36 (0.91–2.03)

.13

1.04 (1.02–1.06)

<.001

  1. aHRs, 95% CI, and P values result from single variable (ie, unadjusted) Cox proportional hazard models. Multivariable models were adjusted for age at diagnosis, sex, ECOG, and number of lines of chemotherapy for OS; adjusted for age at diagnosis and sex for PFS
Back to article page